S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Zacks: Analysts Anticipate Aphria Inc. (NYSE:APHA) Will Post Quarterly Sales of $119.87 Million

Last updated on Monday, November 30, 2020 | 2020 MarketBeat

Equities analysts expect Aphria Inc. (NYSE:APHA) to report sales of $119.87 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Aphria's earnings, with estimates ranging from $115.92 million to $126.46 million. Aphria reported sales of $91.38 million in the same quarter last year, which would suggest a positive year over year growth rate of 31.2%. The company is expected to issue its next earnings report on Tuesday, January 12th.

On average, analysts expect that Aphria will report full-year sales of $509.79 million for the current fiscal year, with estimates ranging from $490.20 million to $542.47 million. For the next financial year, analysts forecast that the firm will report sales of $636.65 million, with estimates ranging from $625.21 million to $664.13 million. Zacks Investment Research's sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Aphria.

Aphria (NYSE:APHA) last announced its earnings results on Thursday, October 15th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.02. The business had revenue of $145.70 million for the quarter, compared to analyst estimates of $159.63 million. Aphria had a net margin of 5.75% and a negative return on equity of 0.30%. The company's revenue for the quarter was up 15.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.07 earnings per share.

A number of equities analysts recently weighed in on APHA shares. Cantor Fitzgerald lowered their price target on shares of Aphria from $15.50 to $11.75 and set an "overweight" rating on the stock in a research report on Friday, October 16th. Zacks Investment Research lowered shares of Aphria from a "hold" rating to a "sell" rating in a research report on Tuesday, November 24th. Finally, CIBC boosted their price target on shares of Aphria from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Friday, November 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of "Buy" and a consensus target price of $8.76.

APHA opened at $7.73 on Monday. The firm has a market capitalization of $2.23 billion, a PE ratio of 85.89 and a beta of 2.19. Aphria has a twelve month low of $1.95 and a twelve month high of $7.78. The firm's 50-day moving average price is $5.40 and its 200 day moving average price is $4.70. The company has a current ratio of 5.19, a quick ratio of 3.73 and a debt-to-equity ratio of 0.25.

A number of large investors have recently bought and sold shares of APHA. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Aphria in the 3rd quarter valued at approximately $75,000. Squarepoint Ops LLC purchased a new stake in shares of Aphria in the 3rd quarter valued at approximately $50,000. ExodusPoint Capital Management LP purchased a new stake in shares of Aphria in the 3rd quarter valued at approximately $174,000. Morgan Stanley raised its stake in shares of Aphria by 37.9% in the 3rd quarter. Morgan Stanley now owns 932,540 shares of the company's stock valued at $4,130,000 after acquiring an additional 256,290 shares during the period. Finally, Great West Life Assurance Co. Can raised its stake in shares of Aphria by 32.3% in the 3rd quarter. Great West Life Assurance Co. Can now owns 45,503 shares of the company's stock valued at $161,000 after acquiring an additional 11,118 shares during the period. Institutional investors own 9.57% of the company's stock.

Aphria Company Profile

Aphria Inc cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands.

Further Reading: The risks of owning bonds

Get a free copy of the Zacks research report on Aphria (APHA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aphria (NYSE:APHA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


20 Stocks Wall Street Analysts Love the Most

Every trading day, between 500 and 800 new recommendations and research reports are issued by sell-side equities research analysts. There are between 300 and 500 brokerages and research houses that issue ratings, price targets and recommendations and more than 5,000 securities around the world that regularly receive coverage from research analysts.

MarketBeat has tracked more than 170,000 distinct analyst recommendations in the last 12 months alone. Given the volume of ratings changes that occur each day, it can be difficult to sift through the noise.

Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when more than a dozen different analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same stock.

This slide show lists the 20 companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.

View the "20 Stocks Wall Street Analysts Love the Most".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.